PMC:7696151 / 116260-116918 JSONTXT

Annnotations TAB JSON ListView MergeView

    LitCovid-PubTator

    {"project":"LitCovid-PubTator","denotations":[{"id":"4103","span":{"begin":78,"end":86},"obj":"Species"},{"id":"4104","span":{"begin":220,"end":228},"obj":"Species"},{"id":"4105","span":{"begin":508,"end":516},"obj":"Species"},{"id":"4106","span":{"begin":570,"end":577},"obj":"Species"},{"id":"4150","span":{"begin":639,"end":642},"obj":"Chemical"},{"id":"4220","span":{"begin":60,"end":68},"obj":"Disease"},{"id":"4221","span":{"begin":69,"end":77},"obj":"Disease"},{"id":"4222","span":{"begin":211,"end":219},"obj":"Disease"},{"id":"4223","span":{"begin":426,"end":431},"obj":"Disease"},{"id":"4224","span":{"begin":541,"end":565},"obj":"Disease"}],"attributes":[{"id":"A4103","pred":"tao:has_database_id","subj":"4103","obj":"Tax:9606"},{"id":"A4104","pred":"tao:has_database_id","subj":"4104","obj":"Tax:9606"},{"id":"A4105","pred":"tao:has_database_id","subj":"4105","obj":"Tax:9606"},{"id":"A4106","pred":"tao:has_database_id","subj":"4106","obj":"Tax:9606"},{"id":"A4150","pred":"tao:has_database_id","subj":"4150","obj":"MESH:D006886"},{"id":"A4220","pred":"tao:has_database_id","subj":"4220","obj":"MESH:C000657245"},{"id":"A4221","pred":"tao:has_database_id","subj":"4221","obj":"MESH:D007239"},{"id":"A4222","pred":"tao:has_database_id","subj":"4222","obj":"MESH:D007239"},{"id":"A4223","pred":"tao:has_database_id","subj":"4223","obj":"MESH:D003643"},{"id":"A4224","pred":"tao:has_database_id","subj":"4224","obj":"MESH:D008133"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Mahévas, et al. (2020) [38] No-randomize clinical study181 COVID-19 infected patients HCQ group -\u003e 600 mg/day for 5 days (n = 84) within 48 h of admission to hospitalControl group (n = 97) Within day 7:20.2% infected patients of the HCQ group and 22.1% in the control group died or were transferred to the ICU;27.4% of the HCQ group and 24.4% of the no-HCQ group shown acute respiratory distress;On day 7 the percentage of death was similar in both HCQ and control group (2.8 vs. 4.8%, 3 vs. 4 events) 7 patients of the HCQ group showed QT interval prolongation.One patient presented first-degreeatrioventricular block after 2 days of HCQ administration."}

    LitCovid-PD-HP

    {"project":"LitCovid-PD-HP","denotations":[{"id":"T277","span":{"begin":378,"end":398},"obj":"Phenotype"}],"attributes":[{"id":"A277","pred":"hp_id","subj":"T277","obj":"http://purl.obolibrary.org/obo/HP_0002098"}],"text":"Mahévas, et al. (2020) [38] No-randomize clinical study181 COVID-19 infected patients HCQ group -\u003e 600 mg/day for 5 days (n = 84) within 48 h of admission to hospitalControl group (n = 97) Within day 7:20.2% infected patients of the HCQ group and 22.1% in the control group died or were transferred to the ICU;27.4% of the HCQ group and 24.4% of the no-HCQ group shown acute respiratory distress;On day 7 the percentage of death was similar in both HCQ and control group (2.8 vs. 4.8%, 3 vs. 4 events) 7 patients of the HCQ group showed QT interval prolongation.One patient presented first-degreeatrioventricular block after 2 days of HCQ administration."}

    LitCovid-sentences

    {"project":"LitCovid-sentences","denotations":[{"id":"T776","span":{"begin":0,"end":658},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Mahévas, et al. (2020) [38] No-randomize clinical study181 COVID-19 infected patients HCQ group -\u003e 600 mg/day for 5 days (n = 84) within 48 h of admission to hospitalControl group (n = 97) Within day 7:20.2% infected patients of the HCQ group and 22.1% in the control group died or were transferred to the ICU;27.4% of the HCQ group and 24.4% of the no-HCQ group shown acute respiratory distress;On day 7 the percentage of death was similar in both HCQ and control group (2.8 vs. 4.8%, 3 vs. 4 events) 7 patients of the HCQ group showed QT interval prolongation.One patient presented first-degreeatrioventricular block after 2 days of HCQ administration."}